Trian Fund Management L.P. Boosts Stake in Solventum Co. (NYSE:SOLV)

Trian Fund Management L.P. grew its position in Solventum Co. (NYSE:SOLV) by 32.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 7,126,255 shares of the company’s stock after acquiring an additional 1,765,676 shares during the period. Solventum accounts for approximately 12.8% of Trian Fund Management L.P.’s investment portfolio, making the stock its 4th biggest position. Trian Fund Management L.P.’s holdings in Solventum were worth $496,842,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Copeland Capital Management LLC bought a new position in shares of Solventum during the third quarter valued at $26,000. Mather Group LLC. bought a new position in shares of Solventum during the third quarter worth about $27,000. EverSource Wealth Advisors LLC acquired a new position in shares of Solventum in the first quarter worth approximately $30,000. Hollencrest Capital Management bought a new stake in Solventum in the second quarter valued at approximately $25,000. Finally, Deseret Mutual Benefit Administrators acquired a new stake in Solventum during the 2nd quarter valued at approximately $25,000.

Wall Street Analysts Forecast Growth

SOLV has been the topic of a number of analyst reports. Wolfe Research began coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. The Goldman Sachs Group lifted their price objective on Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research report on Monday, August 12th. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. Finally, BTIG Research started coverage on Solventum in a report on Thursday, September 5th. They set a “neutral” rating on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average price target of $68.00.

Solventum Trading Up 0.0 %

Shares of NYSE SOLV traded up $0.01 during midday trading on Wednesday, hitting $71.50. 68,725 shares of the stock traded hands, compared to its average volume of 1,691,680. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The business has a 50 day moving average price of $70.51 and a two-hundred day moving average price of $62.40. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.